CN1324243A - 使用热激蛋白治疗炎性疾病的方法 - Google Patents

使用热激蛋白治疗炎性疾病的方法 Download PDF

Info

Publication number
CN1324243A
CN1324243A CN99804346A CN99804346A CN1324243A CN 1324243 A CN1324243 A CN 1324243A CN 99804346 A CN99804346 A CN 99804346A CN 99804346 A CN99804346 A CN 99804346A CN 1324243 A CN1324243 A CN 1324243A
Authority
CN
China
Prior art keywords
heat shock
shock protein
mammal
disease
hsp
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN99804346A
Other languages
English (en)
Chinese (zh)
Inventor
E·W·盖尔芬德
A·F·哈茨库
K·V·卢卡克斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NTIONAL JEWISH MEDICAL AND RESEARCH CENTER
Original Assignee
NTIONAL JEWISH MEDICAL AND RESEARCH CENTER
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by NTIONAL JEWISH MEDICAL AND RESEARCH CENTER filed Critical NTIONAL JEWISH MEDICAL AND RESEARCH CENTER
Publication of CN1324243A publication Critical patent/CN1324243A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Zoology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN99804346A 1998-01-23 1999-01-22 使用热激蛋白治疗炎性疾病的方法 Pending CN1324243A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1233098A 1998-01-23 1998-01-23
US09/012,330 1998-01-23

Publications (1)

Publication Number Publication Date
CN1324243A true CN1324243A (zh) 2001-11-28

Family

ID=21754459

Family Applications (1)

Application Number Title Priority Date Filing Date
CN99804346A Pending CN1324243A (zh) 1998-01-23 1999-01-22 使用热激蛋白治疗炎性疾病的方法

Country Status (16)

Country Link
US (2) US20020006410A1 (https=)
EP (1) EP1049483A1 (https=)
JP (1) JP2002509074A (https=)
KR (1) KR20010040389A (https=)
CN (1) CN1324243A (https=)
AU (1) AU2337499A (https=)
BR (1) BR9907228A (https=)
CA (1) CA2318263A1 (https=)
CZ (1) CZ20002669A3 (https=)
HU (1) HUP0100241A2 (https=)
IL (1) IL137404A0 (https=)
NO (1) NO20003775L (https=)
PL (1) PL342166A1 (https=)
TR (1) TR200002973T2 (https=)
WO (1) WO1999037319A1 (https=)
ZA (1) ZA99499B (https=)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106220718A (zh) * 2016-08-04 2016-12-14 上海市农业科学院 一种草菇热激蛋白VvHSP60及其应用
CN106243203A (zh) * 2016-08-04 2016-12-21 上海市农业科学院 一种草菇热激蛋白VvHSP70及其应用
CN114046596A (zh) * 2021-11-17 2022-02-15 重庆大学 基于trp生化指标检测的室内空气质量控制系统及方法

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7992572B2 (en) 1998-06-10 2011-08-09 Asthmatx, Inc. Methods of evaluating individuals having reversible obstructive pulmonary disease
AU3239400A (en) * 1999-02-22 2000-09-04 University Of Iowa Research Foundation, The Method for inhibiting inflammatory responses
WO2001022816A1 (en) * 1999-09-30 2001-04-05 National Jewish Medical And Research Center MODULATION OF ηδ T CELLS TO REGULATE AIRWAY HYPERRESPONSIVENESS
US6737398B1 (en) 1999-09-30 2004-05-18 National Jewish Medical And Research Center Modulation of γδ T cells to regulate airway hyperresponsiveness
US7235649B2 (en) * 2000-03-24 2007-06-26 Duke University Isolated GRP94 ligand binding domain polypeptide and nucleic acid encoding same, and screening methods employing same
GB0028122D0 (en) * 2000-11-17 2001-01-03 St Georges Entpr Ltd Method
AUPR381601A0 (en) * 2001-03-19 2001-04-12 Monash University Method of treating respiratory conditions
EP1551957A4 (en) * 2001-10-01 2007-01-24 Univ Duke ISOLATED POLYPEPTIDE OF THE GRP94 LIGANDEN BINDING DOMAIN AND NUCLEIC ACID, CRYSTALLINE FORM THEREOF, CODING THEREOF, AND SCRAPPING METHOD WHERE IT IS USED
WO2003068941A2 (en) * 2002-02-13 2003-08-21 Duke University Modulation of immune response by non-peptide binding stress response polypeptides
KR100615389B1 (ko) * 2002-08-23 2006-08-25 (주)헬릭서 다래 추출물을 함유하는 알러지성 질환 및 비알러지성염증 질환의 예방 및 개선용 건강 기능 식품
US20100111927A1 (en) * 2002-08-23 2010-05-06 Sunyoung Kim Compositions Comprising Actinidia and Methods of Use Thereof
GB0226105D0 (en) * 2002-11-08 2002-12-18 St Georges S Entpr Ltd Pain relief agents
CN101330922A (zh) * 2005-10-20 2008-12-24 悉生物有限公司 超敏的治疗
KR100768265B1 (ko) * 2005-11-10 2007-10-17 한국화학연구원 혈액내 순환시간을 향상시키기 위한 헤파린이 수식된리포솜 및 이의 제조방법
AU2009262670B2 (en) 2008-06-26 2013-06-20 Zevra Denmark A/S Use of Hsp70 as a regulator of enzymatic activity
WO2010086418A1 (en) * 2009-01-29 2010-08-05 Alfa Biogene International B.V. Functional food product comprising heat shock protein or a hydrolysate thereof
EP2397074B1 (en) 2010-06-19 2012-10-24 M Stenqvist AB A system and computer readable medium for determination of transpulmonary pressure in a patient connected to a breathing apparatus
CA2817773A1 (en) 2010-11-30 2012-06-07 Orphazyme Aps Methods for increasing intracellular activity of hsp70
WO2012097255A2 (en) * 2011-01-14 2012-07-19 Scott & White Healthcare Therapeutic effect of heat shock proteins in preventing amylin aggregation in type 2 diabetes mellitus
DK2707101T3 (da) 2011-05-12 2019-05-13 Proteostasis Therapeutics Inc Proteostaseregulatorer
US20140228315A1 (en) * 2011-06-16 2014-08-14 Children's Hospital Medical Center Blockade of eosinophil production by toll-like receptors
US10034915B2 (en) 2011-06-23 2018-07-31 The Board Of Trustees Of The Leland Stanford Junior University Small heat shock proteins and active fragments thereof as a therapy for inflammation and ischemia
CA2861464C (en) 2012-01-25 2018-03-06 Proteostasis Therapeutics, Inc. Proteasome activity modulating tricyclic compounds
AU2015317447B2 (en) 2014-09-15 2021-02-25 Zevra Denmark A/S Arimoclomol formulation
EP3402572B1 (en) 2016-01-13 2022-03-16 Children's Hospital Medical Center Compositions and methods for treating allergic inflammatory conditions
US10898476B2 (en) 2016-04-13 2021-01-26 Orphazyme A/S Heat shock proteins and cholesterol homeostasis
DK3782624T3 (da) 2016-04-29 2025-12-15 Zevra Denmark As Arimoclomol til behandling af glucocerebrosidase-associerede lidelser
US11859250B1 (en) 2018-02-23 2024-01-02 Children's Hospital Medical Center Methods for treating eosinophilic esophagitis
EP3781588B1 (en) 2018-04-20 2024-10-30 Children's Hospital Medical Center Blood biomarker for eosinophilic gastrointestinal disorders
CN112585130A (zh) 2018-06-27 2021-03-30 蛋白质平衡治疗股份有限公司 蛋白酶体活性增强化合物
BR112020026580A2 (pt) 2018-06-27 2021-03-23 Proteostasis Therapeutics, Inc. (Fem) Compostos, composição farmacêutica e métodos para tratar um paciente
US12297501B2 (en) 2019-02-25 2025-05-13 Children's Hospital Medical Center Methods for diagnosing and treating eosinophilic gastritis
KR20230128462A (ko) 2020-11-19 2023-09-05 제브라 덴마크 에이/에스 아리모클로몰 시트레이트 및 이의 중간체를 제조하기 위한 공정

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5348945A (en) * 1990-04-06 1994-09-20 Wake Forest University Method of treatment with hsp70
CA2095855C (en) * 1990-11-08 2003-04-29 Graham A.W. Rook Mycobacterium as adjuvant for antigens
GB9211736D0 (en) * 1992-06-03 1992-07-15 Univ Cardiff Allergic treatment
JP4484969B2 (ja) * 1996-11-26 2010-06-16 ヌベンタ バイオファーマスティカル コーポレイション ストレスタンパク質を含む組成物を使用する免疫応答

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106220718A (zh) * 2016-08-04 2016-12-14 上海市农业科学院 一种草菇热激蛋白VvHSP60及其应用
CN106243203A (zh) * 2016-08-04 2016-12-21 上海市农业科学院 一种草菇热激蛋白VvHSP70及其应用
CN106220718B (zh) * 2016-08-04 2019-12-10 上海市农业科学院 一种草菇热激蛋白VvHSP60及其应用
CN106243203B (zh) * 2016-08-04 2019-12-10 上海市农业科学院 一种草菇热激蛋白VvHSP70及其应用
CN114046596A (zh) * 2021-11-17 2022-02-15 重庆大学 基于trp生化指标检测的室内空气质量控制系统及方法

Also Published As

Publication number Publication date
HUP0100241A2 (hu) 2001-06-28
ZA99499B (en) 1999-07-22
US20070179087A1 (en) 2007-08-02
EP1049483A1 (en) 2000-11-08
CA2318263A1 (en) 1999-07-29
IL137404A0 (en) 2001-07-24
NO20003775L (no) 2000-09-22
AU2337499A (en) 1999-08-09
CZ20002669A3 (cs) 2001-11-14
WO1999037319A1 (en) 1999-07-29
PL342166A1 (en) 2001-05-21
JP2002509074A (ja) 2002-03-26
KR20010040389A (ko) 2001-05-15
BR9907228A (pt) 2000-10-24
TR200002973T2 (tr) 2001-02-21
US20020006410A1 (en) 2002-01-17
NO20003775D0 (no) 2000-07-21

Similar Documents

Publication Publication Date Title
CN1324243A (zh) 使用热激蛋白治疗炎性疾病的方法
Smaldone Repurposing of gamma interferon via inhalation delivery
Won et al. Inhaled delivery of Interferon-lambda restricts epithelial-derived Th2 inflammation in allergic asthma
JP2013545751A (ja) 修飾された免疫調節粒子
US20240076393A1 (en) Regulating il-4 and il-13 levels by blocking high affinity binding by il-3, il-5 and gm-csf to their common receptor
US20140249087A1 (en) Use of hemopexin to sequester hemoglobin
JP2021512905A (ja) 寛容化粒子によるセリアック病の治療
US6248723B1 (en) Method for treatment of inflammatory disease
US20010007758A1 (en) Treatment of multiple sclerosis using COP-1 and Th2-enhancing cytokines
CN108367163A (zh) 用于治疗干眼及相关眼表疾病的治疗性组合物
US20070253975A1 (en) Methods for preventing strokes by inducing tolerance to E-selectin
JP2010527354A (ja) 免疫調節化合物によるアレルギー性疾患の治療
SA95160081B1 (ar) طريقة لعلاج امراض المناعة الذاتية auto-immune diseases باستعمال انترفيرونات من النوع 1 type one interferon
Li et al. Therapeutic effects of DNA vaccine on allergen-induced allergic airway inflammation in mouse model
JP6762524B2 (ja) 嚢胞性線維症の治療における使用のためのチモシンα１
Kodama et al. Role of interleukin-12 in the regulation of CD4+ T cell apoptosis in a mouse model of asthma
WO2005004914A1 (ja) NF-κBデコイを含む呼吸器疾患用治療および予防のための薬学的組成物およびその使用方法
US20020141995A1 (en) Method for treatment of inflammatory disease
AU2001264813A1 (en) Methods for preventing strokes by inducing tolerance to E-selectin
US20230226095A1 (en) Methods and compositions for treating coronavirus infectious disease
MXPA00007148A (es) Metodo para el tratamiento de enfermedades inflamatorias usando proteinas de choque termico
US20220273768A1 (en) Intranasal leptin compositions and methods of use thereof for prevention of opioid induced respiratory depression in obesity
AU2005235514B2 (en) Pharmaceutical formulations and methods for preventing or treating damage to brain tissue
WO2024164213A1 (zh) 聚乙二醇修饰的白介素2、糖皮质激素和透明质酸用于治疗特应性皮炎

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication